Algert Global LLC continued to hold its position in shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 73,335 shares of the biotechnology company’s stock at the end of the second quarter. Algert Global LLC’s holdings in Applied Genetic Technologies Corporation were worth $374,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in AGTC. CAPROCK Group Inc. increased its position in shares of Applied Genetic Technologies Corporation by 55.8% in the first quarter. CAPROCK Group Inc. now owns 17,215 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,165 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Applied Genetic Technologies Corporation during the first quarter worth about $123,000. Wells Fargo & Company MN increased its position in shares of Applied Genetic Technologies Corporation by 1.1% in the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after buying an additional 200 shares in the last quarter. Smith Asset Management Group LP bought a new position in shares of Applied Genetic Technologies Corporation during the first quarter worth about $141,000. Finally, Credit Suisse AG increased its position in shares of Applied Genetic Technologies Corporation by 10.9% in the first quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after buying an additional 2,662 shares in the last quarter. Institutional investors and hedge funds own 62.22% of the company’s stock.

Applied Genetic Technologies Corporation (NASDAQ AGTC) opened at 4.95 on Friday. Applied Genetic Technologies Corporation has a 52 week low of $4.50 and a 52 week high of $15.78. The stock has a market capitalization of $89.48 million, a P/E ratio of 11.81 and a beta of 1.68. The company’s 50-day moving average price is $4.96 and its 200 day moving average price is $6.07.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by $0.04. Applied Genetic Technologies Corporation had a net margin of 17.61% and a return on equity of 6.62%. The business had revenue of $8.39 million during the quarter, compared to analyst estimates of $10.39 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The firm’s quarterly revenue was down 30.1% on a year-over-year basis. Equities research analysts expect that Applied Genetic Technologies Corporation will post $0.33 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Algert Global LLC Has $374,000 Stake in Applied Genetic Technologies Corporation (AGTC)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2017/08/12/algert-global-llc-has-374000-stake-in-applied-genetic-technologies-corporation-agtc.html.

AGTC has been the topic of several research analyst reports. Stifel Nicolaus dropped their target price on Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 11th. HC Wainwright set a $16.00 target price on Applied Genetic Technologies Corporation and gave the stock a “buy” rating in a research note on Thursday. ValuEngine downgraded Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Cantor Fitzgerald set a $15.00 target price on Applied Genetic Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, May 10th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Applied Genetic Technologies Corporation presently has an average rating of “Buy” and a consensus target price of $13.81.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corporation (NASDAQ:AGTC).

Institutional Ownership by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.